Sunshine Biopharma Inc.
Here’s whether Sunshine Biopharma Inc. (SBFM) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-10.69% over 10 days); RSI 29 — oversold; weak 1-year return of -65.6%; 3-month momentum negative (-58.9%); rising volume on a downtrend (distribution, 3.00x avg). Currently 80.2% off its 52-week high. Score: -7/7.
SBFM is trading below its 200-day MA ($1.31) — a key warning sign the longer-term trend is under pressure. An RSI of 28.9 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -65.6% compares to +27.9% for SPY (trailed the market by 93.5%). The current 80.2% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.